Law firm seeks lead plaintiff in securities class action against Beta Bionics
The Law Offices of Frank R. Cruz says investors who lost money on Beta Bionics, Inc. (BBNX) have a chance to lead a securities fraud class action. The complaint alleges the company and other defendants misled investors about FDA findings tied to its iLet device.
- The Law Offices of Frank R. Cruz says investors with BBNX losses can seek to lead a securities fraud class action.
- The complaint covers July 30, 2025 to February 24, 2026 and alleges misleading statements about the business.
- It alleges the company did not disclose an FDA Form 483 identifying over 18,000 complaints tied to the iLet.
- The lead plaintiff deadline stated in the release is November 3, 2026.
- Investors need not act to remain absent class members, and the allegations are unproven.
What the complaint alleges
According to the press release, the complaint covers the period between July 30, 2025 and February 24, 2026. It alleges that during that time the defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the company's business, operations and prospects.
The release lists several specific allegations. These are claims made in the complaint, not findings by a court.
- The defendants allegedly omitted any mention of the FDA Form 483 and the underlying safety issues with the iLet. The release says the Form 483 identified over 18,000 complaints, including numerous life-threatening hypoglycemic events that the company had "failed to investigate" or even report to the FDA, with no justification.
- The company allegedly assured investors that its remediation efforts were advanced and that the FDA's issues were "very benign". The complaint says this did not accurately describe the scope and severity of the FDA's observations, which made remediation much more complex and extensive than investors were told.
- A statement that the company "could have opened a CAPA and did not" is alleged to have been misleading, because the FDA had in fact concluded that Beta Bionics had, without justification, failed to investigate clearly serious, life-threatening customer reports.
- As a result, the defendants' positive statements about the business, operations and prospects were allegedly materially misleading and/or lacked a reasonable basis.
Lead plaintiff deadline and how to take part
The release gives a lead plaintiff deadline of November 3, 2026. The lead plaintiff is the investor who represents the wider group of shareholders in the case. The law firm invites investors who suffered losses in BBNX to contact it to participate or learn more.
Contact details in the release are an email address, the telephone number 310-914-5007, and the website www.frankcruzlaw.com. The firm also posts updates on Twitter at twitter.com/FRC_LAW. Investors who inquire by email are asked to include their mailing address, telephone number and number of shares purchased.
What it means for shareholders
The release states that people do not need to act now to be part of the class action. Investors may retain counsel of their choice, or take no action and remain an absent member of the class.
The announcement comes from a law firm, not from Beta Bionics or a court, and it is labeled as possible attorney advertising in some jurisdictions. The allegations remain unproven, and the release does not include a response from the company. Shareholders who bought BBNX during the stated period and want to understand their rights are pointed to the firm or to independent counsel.
